Abstract:Purpose: To evaluate the accuracy and the predictive value of 18F-FDG PET or PET/CT in the assessment of neoadjuvant chemotherapy (NAC) in locally advanced breast cancer by meta-analysis. Materials and Methods: Relevant studies were identified by systematic searches of PUBMED and COCHRANE databases, published in English. To ensure homogeneity of all included studies, selection criteria were established and all the studies were scored according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria. Meta-analysis was done on the diagnostic performance data from eligible studies. Draw funnel plots to explore the publication bias. Draw forest plots to exclude abnormal data(s). Use Spearman correlation coefficients p, likelihood ratio x2 test and I2 index in order to indicate heterogeneity. Estimate and compare the weighted summary sensitivities (SEs), specificities (SPs), diagnostic odds ratios (DORs), and summary receiver operating characteristic (SROC) curves of PET and other examinations (measuring the size of tumor). Subgroup analyses were performed to identify heterogeneity potential sources. Do Z test to find significant difference between each results. Results: 27 groups of data in 19 eligible studies were included with a total of 1164 subjects evaluated by 18F-FDG PET or PET/CT and 291 ones evaluated by other examinations. Funnel plots showed the existence of publication bias. Spearman correlation coefficients p, likelihood ratio x2 test and I2 index explored the heterogeneity. The Results of the Weighted Summary: SEPET was significantly higher than SED [83.7% (329/393) vs. 59.0% (98/166), p SPPET was significantly higher than SPD [66.8% (512/766) vs. 40.8% (51/125), p DORPET was significantly higher than DORD (14.02 vs. 1.29, p AUCPET and Q*PET were both significantly higher than AUCD and Q*D (AUCs 0.8838 vs. 0.6046; Q*s 0.8143 vs. 0.5788, p st or 2nd cycle of NAC was a litter better than later with higher SE (p = 0.083). Standardized uptake value (SUV) reduction rate between 40% and 45% as FDG-PET response threshold value was used for its highest SP (p = 0.01), while no significant difference was found comparing SEs and DORs (p > 0.05). Trend of higher SE and lower SP were found at ER negative breast cancers than ER positive ones (SEs 93.94% vs. 83.33%; SPs 35.76% vs. 62.24%), though Z test did not find significant difference (p > 0.05). Conclusion: This meta-analysis showed that FDG-PET or PET/CT does have a higher global accuracy in assessing the response for NAC in breast cancer. Comparing with clinical response, metabolic response plays a potential role in directing therapy for breast cancer. Factors which affected the accuracy of FDG-PET assessment included PET timing point, SUV reduction rate as threshold value and ER expression.

Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

FDG PET-CT for the Detection of Occult Nodal Metastases in Head and Neck Cancer: A Systematic Review and Meta-Analysis

Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules

F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial

Novel Diagnostic Approaches for Assessment of the Clinically Negative Neck in Head and Neck Cancer Patients

The Neck-Persistency-Net: a three-dimensional, convolution, deep neural network aids in distinguishing vital from non-vital persistent cervical lymph nodes in advanced head and neck squamous cell carcinoma after primary concurrent radiochemotherapy

FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review

Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI

Treatment Strategies Guided by [18F]FDG-PET/CT in Patients with Locally Advanced Cervical Cancer and [18F]FDG-Positive Lymph Nodes

Meta-Analysis: <sup>18</sup>F-FDG PET or PET/CT for the Evaluation of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography for the Identification of Cervical Nodal Metastases of Head and Neck Cancer Compared with Computed Tomography/magnetic Resonance Imaging and Clinical Palpation in 40 Cases

Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Performance of FDG PET/CT in the Clinical Management of Breast Cancer

FDG-PET, CT, MRI for Diagnosis of Local Residual or Recurrent Nasopharyngeal Carcinoma, Which One is the Best? A Systematic Review

PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer

Head-to-head comparison of 18 F-FDG PET/CT and 18 F-FDG PET/MRI for lymph node metastasis staging in non-small cell lung cancer: a meta-analysis

An Analysis of 18F-Fluorodexyglucose (18F-FDG) Positron Emission Tomography on Monitoring Therapeutic Outcome in 21 Case with Nasopharyngeal Carcinoma after Radiotherapy

Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications

PET/CT Versus Standard Imaging for Prediction of Survival in Patients with Recurrent Head and Neck Squamous Cell Carcinoma